Flavivirus IgM Detection via Antiparallel Protein E Dimer Complex
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting flavivirus-specific IgM antibodies in patient samples are limited by interference from rheumatoid factors and non-specific reactions, and require handling of infectious agents or expensive, unstable virus-like particles, which complicates the diagnosis of recent flavivirus infections.
Innovation Solution
A method involving a solid support with immobilized IgM-binding molecules, where a preformed complex of an antiparallel dimer of soluble flavivirus Protein E and a marker is used to specifically detect IgM antibodies by binding to immobilized IgM antibodies, enhancing sensitivity and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If indirect ELISA is used for detecting IgM antibodies, then the assay can detect flavivirus-specific antibodies, but rheumatoid factors and non-specific reactions cause interference reducing diagnostic accuracy
Solution Approach 1:
The patent introduces an IgM-specific capture antibody as an intermediary layer between the solid phase and the patient serum. This mediator specifically binds IgM antibodies while preventing interference from rheumatoid factors and other non-specific reactions, thereby improving diagnostic accuracy without sacrificing sensitivity
Solution Approach 2:
The assay is divided into distinct functional layers: a capture antibody layer for specific IgM binding, a patient serum layer containing the target antibodies, and a detection layer with flavivirus-specific antibodies. This segmentation allows each layer to perform its specific function independently, eliminating cross-interference and improving measurement precision
2Reliability
If virus-like particles are used as antigens, then the assay can detect neutralizing antibodies, but the particles are expensive and unstable complicating standardization
Solution Approach 1:
The patent extracts only the essential antigenic components (flavivirus envelope proteins E and M) from the complex virus-like particle structure. These extracted proteins are produced recombinantly as purified components, eliminating the instability and manufacturing complexity of whole virus-like particles while retaining the ability to detect neutralizing antibodies
Solution Approach 2:
Instead of using complex virus-like particles, the patent uses recombinantly produced envelope proteins that copy only the essential antigenic determinants needed for neutralizing antibody detection. This simplified copy is more stable, easier to manufacture, and allows for better standardization while maintaining detection reliability
3Measurement precision
If infectious flavivirus agents are handled for assay development, then specific IgM antibodies can be detected, but biosafety risks and handling complexity increase
Solution Approach 1:
The patent extracts the essential antigenic information from infectious flavivirus agents and represents it using recombinant envelope proteins. This extraction eliminates the biosafety risks associated with handling infectious agents while preserving the ability to detect specific IgM antibodies with high sensitivity
Solution Approach 2:
The patent creates non-infectious recombinant copies of the flavivirus envelope proteins that contain all necessary antigenic determinants for IgM detection. These copies eliminate biosafety hazards while maintaining measurement precision, allowing routine diagnostic use without specialized biosafety facilities
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a highly sensitive and specific detection system for flavivirus IgM antibodies, capable of distinguishing between different flaviviruses, including dengue and Zika viruses, and detecting serotype-specific infections, with improved stability and standardization of components.
Implementation Method 1
contacting the sample with a solid support comprising immobilised IgM-binding molecules, allowing binding of IgM antibodies in the sample to the IgM binding molecules on the solid support
Implementation Method 2
detecting IgM antibodies specific for a flavivirus by allowing binding of a complex comprising (i) an antiparallel dimer of soluble flavivirus Protein E (sE) and (ii) a marker
Data Source
Figure 1A~1C
Figure 2
Figure 3~4B
AI summary
Disclosed is a method for the detection of an IgM antibody specific for a flavivirus in a sample, comprising the steps of (a) contacting the sample with a solid support comprising immobilised IgM-binding molecules, (b) allowing binding of IgM antibodies in the sample to the IgM binding molecules on the solid support so that the IgM antibodies are also immobilised on the solid support, and (c) detecting IgM antibodies specific for a flavivirus by allowing binding of a complex comprising (i) an antiparallel dimer of soluble flavivirus Protein E (sE) and (ii) a marker and identifying the binding of the complex to the specific flavivirus IgM antibody by detecting the marker; and a kit suitable for performing the method.